ClinicalTrials.gg
TerminatedNCT04577963Updated Jul 14, 2025Results posted

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

A Phase 1/2 interventional study of Fruquintinib and Tislelizumab in Triple Negative Breast Cancer, Endometrial Cancer and Solid Tumor, Unspecified, Adult, sponsored by Hutchmed. Terminated at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Hutchmed · Phase 1/2, Interventional, and Treatment

Why this study was terminated
At the time of study termination, both fruquintinib and tislelizumab are commercially available in the United States.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing tislelizumab in Triple Negative Breast Neoplasms — 6 open to participants now, 8 under way, none of them phase 3. tislelizumab · Triple Negative Breast Neoplasms.

Enrollment
7th of 12
52 · median 65
Started
2021
with 3 others
Phase 1/2
3 of 12
2 open now
Registered
2nd of 12
by date
Lead sponsor
1 of 12
Hutchmed

Among the 12 studies testing tislelizumab in Triple Negative Breast Neoplasms, this one is the 7th largest by enrollment, is one of 4 that started in 2021, is one of 3 in phase 1/2, and was the 2nd registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

6 of the 12 studies testing tislelizumab in Triple Negative Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tislelizumab in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with locally advanced or metastatic solid tumors. This study will be conducted in 2 parts; a Safety Lead-in Phase (Part 1) and a Dose Expansion Phase (Part 2).

The Safety Lead-in Phase, open to any-comer solid tumors, will determine the RP2D. The RP2D will be administered to 3 cohorts of patients in the Dose Expansion Phase.

  • Cohort A: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-treated)
  • Cohort B: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-Naïve)
  • Cohort C: Advanced or Metastatic Endometrial Cancer (EC) (IO-Naïve)
  • Cohort D: Advanced or Metastatic Colorectal Cancer (mCRC) (IO-Naïve)
03

Conditions studied

  • Triple Negative Breast Cancer
  • Endometrial Cancer
  • Solid Tumor, Unspecified, Adult
  • Colorectal Cancer

Keywords

  • Breast cancer
  • Triple negative
  • Her2-
  • HR-
  • ER-
  • PR-
  • Her2 negative
  • HR negative
  • ER negative
  • PR negative
  • TNBC
  • VEGF
  • VEGFR
  • Endometrial cancer
  • Colon
  • Rectal
  • mCRC
  • Colorectal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide signed by study patient or legally acceptable representative, as specified by health authorities and institutional guidelines;
  2. Age ≥18 years;
  3. or cytologically documented, advanced or Triple Negative Breast Cancer, histologically or cytologically documented, advanced or metastatic endometrial carcinoma, histologically or cytologically confirmed advanced or metastatic, unresectable adenocarcinoma of the colon or rectum.
  4. Tumor tissue (archival or fresh tumor tissues as formalin-fixed paraffin-embedded blocks or approximately 15 unstained slides) for central laboratory assessment.
  5. (ECOG) Performance Status ≤1.
  6. At least 1 as defined by v1.1.

Exclusion criteria

Exclusion Criteria:

  1. Has at screening any central nervous system and/or .
  2. Except for Cohort A, Prior therapy targeting , PD-1, PD-L1 or programmed cell death protein ligand-2 (PD-L2) or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
  3. Prior treatment with a VEGFR-TKI or anti-VEGFR antibody (eg, ramucirumab).
  4. Except for Cohort D, prior treatment with an anti-VEGFR antibody (eg, bevacizumab).
  5. Tumor tissue (archival or fresh tumor tissues as formalin-fixed paraffin-embedded blocks or approximately 15 unstained slides) for central laboratory assessment.
  6. Active diseases or history of autoimmune diseases that may relapse, or history of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including but not limited to pulmonary fibrosis, acute lung diseases, etc.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Part 1

    Approximately 6-12 patients with locally advanced or metastatic solid tumors will be enrolled to receive fruquintinib in combination with tislelizumab and assessed for DLTs during the 28-day DLT observation period

    Drug: Fruquintinib · Drug: Tislelizumab

  • Experimental
    Part 2

    Patients will be enrolled to one of the following expansion cohorts: * Cohort A: TNBC (immuno-oncology \[IO\]-treated in the metastatic setting) * Cohort B: TNBC (IO-Naïve in the metastatic setting) * Cohort C: EC * Cohort D: MSS CRC

    Drug: Fruquintinib · Drug: Tislelizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Patients With Dose-Limiting Toxicities (DLTs)

    According to National Cancer Institute Common Terminology Criteria for Adverse Events(AEs) v5.0, DLT was defined as any 1 of following toxicities during DLT assessment window and considered by Investigator to be related to 1 or more study treatments:a)Hematologic: grade(G) 4 neutropenia lasting \>7 days, G ≥3 febrile neutropenia, G 3 thrombocytopenia with clinically significant bleeding, G 4 thrombocytopenia, G ≥4 anemia.b) Non-hematologic:all G ≥3 non-hematologic toxicities except:G 3 endocrinopathy controlled by hormonal replacement with no hospitalization and resolved to G ≤1 within 7 days, G 3 nausea/vomiting or diarrhea for \<72 hours with antiemetic and supportive care, G 3 fatigue for \<1 week, G ≥3 electrolyte abnormality lasting up to 72 hours and resolving with treatment, G 3 rash returning to baseline or G ≤1 within 7 days with treatment,G ≥3 amylase or lipase elevation without symptoms of pancreatitis,G 3 hypertension returning to baseline or G≤1 within 7 days with treatment.

    Time frame: From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (cycle duration: 4 weeks)

  2. Part 1: Recommended Phase 2 Dose (RP2D) of Fruquintinib in Combination With Tislelizumab

    The RP2D of fruquintinib in combination with tislelizumab based on the safety and tolerability assessments in Part 1 patients.

    Time frame: From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (cycle duration: 4 weeks)

  3. Part 2: Objective Response Rate (ORR)

    The ORR was defined as the percentage of patients with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator using RECIST v1.1. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 millimeters (mm). The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months

Secondary outcomes

  1. Part 1: Objective Response Rate

    The ORR was defined as the percentage of patients with a confirmed BOR of CR or PR as determined by the investigator using RECIST v1.1. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months

  2. Parts 1 and 2: Progression-free Survival (PFS)

    PFS was defined as the time from the start of study treatment until the first radiographic documentation of objective progression as assessed by the investigator using RECIST v1.1, or death from any cause. The PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression.

    Time frame: Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months

  3. Parts 1 and 2: Disease Control Rate (DCR)

    The DCR was defined as the percentage of patients with a BOR of CR, PR, or stable disease (SD) lasting for at least 7 weeks as determined by the investigator using RECIST v1.1. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.

    Time frame: Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months

  4. Parts 1 and 2: Clinical Benefit Rate (CBR)

    The CBR was defined as the percentage of patients with a BOR of CR, PR, or durable SD (i.e., lasting for at least 6 months) as determined by the investigator using RECIST v1.1. Durable SD was SD for at least 6 months. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.

    Time frame: Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months

  5. Parts 1 and 2: Duration of Response (DoR)

    The DoR was defined as the time from the first occurrence of PR or CR by RECIST v1.1, whichever came first until PD or death. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression.

    Time frame: Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months

  6. Parts 1 and 2: Overall Survival (OS)

    The OS was defined as the time from start of study treatment until the date of death due to any cause.

    Time frame: From the first dose of study treatment (Day 1) up to date of death due to any cause, up to a maximum of approximately 34 months

  7. Parts 1 and 2: Plasma Concentrations of Fruquintinib and Metabolite M11

    Blood samples were collected at the specified timepoints to determine plasma concentrations of fruquintinib and metabolite M11.

    Time frame: Pre-dose on Days 1, 8, 15, 21 of Cycle 1 and on Day 1 of Cycles 2, 4, 7, 13; 2 to 4 hours post-dose on Days 1 and 21 of Cycle 1 (cycle duration: 4 weeks)

  8. Parts 1 and 2: Serum Concentrations of Tislelizumab

    Blood samples were collected at the specified timepoints to determine serum concentrations of tislelizumab.

    Time frame: Pre-infusion on Day 1 of Cycles 1, 2, 4, 7, 13; at end of infusion on Day 1 of Cycles 1 and 4; on Days 8, 15, and 21 of Cycle 1 (cycle duration: 4 weeks)

  9. Parts 1 and 2: Number of Patients With Antidrug Antibodies (ADAs) to Tislelizumab

    Blood samples were collected at the specified timepoints to detect ADAs to tislelizumab. Treatment-induced ADA was defined as ADA negative at baseline and ADA positive post-baseline. Treatment-boosted ADA was defined as ADA positive at baseline that was boosted to a 4-fold or higher-level following treatment administration.

    Time frame: From the first dose of study treatment (Day 1) up to end of treatment, up to approximately 17 months for Part 1 and 20 months for Part 2

  10. Part 2: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Treatment Discontinuation

    An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment, whether or not considered related to the treatment. An AE was considered "serious" if, in the view of either the investigator or sponsor, it resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, was a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, was an abnormal pregnancy outcome in a child born to a female patient/female partner of a male patient exposed to study treatment or was an important medical event. TEAEs were AEs that started or worsened in severity on or after the first dose of study treatment and up to 30 days after the date of last study treatment administration.

    Time frame: From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 21 months

  11. Part 2: Change From Baseline in Programmed Death-Ligand 1 (PD-L1) Expression

    Expression of PD-L1 biomarker was planned to be assessed in tumor tissues of the patients. Baseline was defined as the last non-missing assessment prior to the first administration of any study treatment (whichever occurred first), including scheduled and unscheduled visits, unless otherwise specified.

    Time frame: Baseline (Day 1) up to end of treatment, up to approximately 20 months

07

Results

Posted Jul 14, 2025
Limitations and caveats
The study was terminated early based upon the strategic evaluation of clinical development of fruquintinib in the United States. This change was not based on any concern for patient safety or efficacy relative to fruquintinib and/or tislelizumab treatment.

Participant flow

This phase 1b/2, 2-part, open-label study was conducted in patients with advanced or metastatic solid tumors.

Part 1
Participant flow — Part 1
MilestonePart 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting)Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)
Started60000
Completed60000
Not completed00000
Part 2
Participant flow — Part 2
MilestonePart 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting)Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)
Started0111139
Completed00000
Not completed0111139
Withdrew: Death018020
Withdrew: Lost to follow-up00002
Withdrew: Withdrawal by subject000010
Withdrew: Progressive disease00002
Withdrew: Investigator decision00001
Withdrew: Sponsor terminated study00314

Outcome measures

PrimaryPart 1: Number of Patients With Dose-Limiting Toxicities (DLTs)

According to National Cancer Institute Common Terminology Criteria for Adverse Events(AEs) v5.0, DLT was defined as any 1 of following toxicities during DLT assessment window and considered by Investigator to be related to 1 or more study treatments:a)Hematologic: grade(G) 4 neutropenia lasting \>7 days, G ≥3 febrile neutropenia, G 3 thrombocytopenia with clinically significant bleeding, G 4 thrombocytopenia, G ≥4 anemia.b) Non-hematologic:all G ≥3 non-hematologic toxicities except:G 3 endocrinopathy controlled by hormonal replacement with no hospitalization and resolved to G ≤1 within 7 days, G 3 nausea/vomiting or diarrhea for \<72 hours with antiemetic and supportive care, G 3 fatigue for \<1 week, G ≥3 electrolyte abnormality lasting up to 72 hours and resolving with treatment, G 3 rash returning to baseline or G ≤1 within 7 days with treatment,G ≥3 amylase or lipase elevation without symptoms of pancreatitis,G 3 hypertension returning to baseline or G≤1 within 7 days with treatment.

Time frame:
From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (cycle duration: 4 weeks)
Reported as:
Count of participants · Participants
Part 1: Number of Patients With Dose-Limiting Toxicities (DLTs)
ParticipantsPart 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting)
Part 1: Number of Patients With Dose-Limiting Toxicities (DLTs)1
PrimaryPart 1: Recommended Phase 2 Dose (RP2D) of Fruquintinib in Combination With Tislelizumab

The RP2D of fruquintinib in combination with tislelizumab based on the safety and tolerability assessments in Part 1 patients.

Time frame:
From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (cycle duration: 4 weeks)
Reported as:
Number · mg
Part 1: Recommended Phase 2 Dose (RP2D) of Fruquintinib in Combination With Tislelizumab
mgPart 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting)
Part 1: Recommended Phase 2 Dose (RP2D) of Fruquintinib in Combination With Tislelizumab5
PrimaryPart 2: Objective Response Rate (ORR)

The ORR was defined as the percentage of patients with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator using RECIST v1.1. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 millimeters (mm). The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months
Reported as:
Number · percentage of patients
Part 2: Objective Response Rate (ORR)
percentage of patientsPart 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)
Part 2: Objective Response Rate (ORR)0 (NA to NA)27.3 (6.0 to 61.0)0 (NA to NA)5.1 (0.6 to 17.3)
SecondaryPart 1: Objective Response Rate

The ORR was defined as the percentage of patients with a confirmed BOR of CR or PR as determined by the investigator using RECIST v1.1. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months
Reported as:
Number · percentage of patients
Part 1: Objective Response Rate
percentage of patientsPart 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting)
Part 1: Objective Response Rate16.7 (0.4 to 64.1)
SecondaryParts 1 and 2: Progression-free Survival (PFS)

PFS was defined as the time from the start of study treatment until the first radiographic documentation of objective progression as assessed by the investigator using RECIST v1.1, or death from any cause. The PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression.

Time frame:
Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months
Reported as:
Median · months
Parts 1 and 2: Progression-free Survival (PFS)
monthsPart 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting)Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)
Parts 1 and 2: Progression-free Survival (PFS)3.8 (1.8 to NA)NA (NA to NA)5.0 (1.8 to 7.4)5.5 (NA to NA)3.6 (2.0 to 5.6)
SecondaryParts 1 and 2: Disease Control Rate (DCR)

The DCR was defined as the percentage of patients with a BOR of CR, PR, or stable disease (SD) lasting for at least 7 weeks as determined by the investigator using RECIST v1.1. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.

Time frame:
Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months
Reported as:
Number · percentage of patients
Parts 1 and 2: Disease Control Rate (DCR)
percentage of patientsPart 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting)Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)
Parts 1 and 2: Disease Control Rate (DCR)50.0 (11.8 to 88.2)0 (NA to NA)72.7 (39.0 to 94.0)100 (2.5 to 100)53.8 (37.2 to 69.9)
SecondaryParts 1 and 2: Clinical Benefit Rate (CBR)

The CBR was defined as the percentage of patients with a BOR of CR, PR, or durable SD (i.e., lasting for at least 6 months) as determined by the investigator using RECIST v1.1. Durable SD was SD for at least 6 months. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.

Time frame:
Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months
Reported as:
Number · percentage of patients
Parts 1 and 2: Clinical Benefit Rate (CBR)
percentage of patientsPart 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting)Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)
Parts 1 and 2: Clinical Benefit Rate (CBR)16.7 (0.4 to 64.1)0 (NA to NA)27.3 (6.0 to 61.0)0 (NA to NA)20.5 (9.3 to 36.5)
SecondaryParts 1 and 2: Duration of Response (DoR)

The DoR was defined as the time from the first occurrence of PR or CR by RECIST v1.1, whichever came first until PD or death. The CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression.

Time frame:
Tumor assessments performed every 8 weeks (+/-1 week) until PD, up to a maximum of approximately 34 months
Reported as:
Median · months
Parts 1 and 2: Duration of Response (DoR)
monthsPart 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting)Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)
Parts 1 and 2: Duration of Response (DoR)14.9 (NA to NA)—14.9 (6.0 to NA)—NA (NA to NA)
SecondaryParts 1 and 2: Overall Survival (OS)

The OS was defined as the time from start of study treatment until the date of death due to any cause.

Time frame:
From the first dose of study treatment (Day 1) up to date of death due to any cause, up to a maximum of approximately 34 months
Reported as:
Median · months
Parts 1 and 2: Overall Survival (OS)
monthsPart 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting)Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)
Parts 1 and 2: Overall Survival (OS)16.4 (12.0 to NA)25.8 (NA to NA)14.1 (5.0 to NA)NA (NA to NA)10.2 (7.1 to 11.7)
SecondaryParts 1 and 2: Plasma Concentrations of Fruquintinib and Metabolite M11

Blood samples were collected at the specified timepoints to determine plasma concentrations of fruquintinib and metabolite M11.

Time frame:
Pre-dose on Days 1, 8, 15, 21 of Cycle 1 and on Day 1 of Cycles 2, 4, 7, 13; 2 to 4 hours post-dose on Days 1 and 21 of Cycle 1 (cycle duration: 4 weeks)
Reported as:
Mean · nanograms per milliliter
Parts 1 and 2: Plasma Concentrations of Fruquintinib and Metabolite M11
nanograms per milliliterPart 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting)Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)
Fruquintinib: Cycle 1 Day 1: Pre-dose0 ± 0—0 ± 00 ± 00 ± 0
Fruquintinib: Cycle 1 Day 1: 2 to 4 hours post-dose5.49 ± NA—56.2 ± 52.9125 ± NA70.7 ± 34.3
Fruquintinib: Cycle 1 Day 8: Pre-dose——222 ± 29.0—195 ± 57.0
Fruquintinib: Cycle 1 Day 15: Pre-dose——240 ± 72.7263 ± NA177 ± 37.7
Fruquintinib: Cycle 1 Day 21: Pre-dose252 ± NA—216 ± 59.5—186 ± 51.4
Fruquintinib: Cycle 1 Day 21: 2 to 4 hours post-dose327 ± NA—327 ± NA—267 ± 66.4
Fruquintinib: Cycle 2 Day 1: Pre-dose——23.2 ± 15.315.2 ± NA17.0 ± 17.7
Fruquintinib: Cycle 4 Day 1: Pre-dose——5.12 ± NA—15.3 ± 8.89
Fruquintinib: Cycle 7 Day 1: Pre-dose————28.6 ± 19.1
Fruquintinib: Cycle 13 Day 1: Pre-dose————12.3 ± NA
M11: Cycle 1 Day 1: Pre-dose0 ± 0—0 ± 00 ± 00 ± 0
M11: Cycle 1 Day 1: 2 to 4 hours post-dose0 ± 0—0.415 ± 0.6432.71 ± NA0.413 ± 0.766
M11: Cycle 1 Day 8: Pre-dose——84.2 ± 53.5—60.7 ± 34.7
M11: Cycle 1 Day 15: Pre-dose——87.3 ± 32.4139 ± NA74.6 ± 45.9
M11: Cycle 1 Day 21: Pre-dose148 ± NA—106 ± 40.0—66.1 ± 28.0
M11: Cycle 1 Day 21: 2 to 4 hours post-dose124 ± NA—124 ± NA—69.1 ± 25.4
M11: Cycle 2 Day 1: Pre-dose——30.8 ± 12.640.5 ± NA20.5 ± 14.4
M11: Cycle 4 Day 1: Pre-dose——16.6 ± NA—19.3 ± 10.4
M11: Cycle 7 Day 1: Pre-dose————31.4 ± 8.60
M11: Cycle 13 Day 1: Pre-dose————11.7 ± NA
SecondaryParts 1 and 2: Serum Concentrations of Tislelizumab

Blood samples were collected at the specified timepoints to determine serum concentrations of tislelizumab.

Time frame:
Pre-infusion on Day 1 of Cycles 1, 2, 4, 7, 13; at end of infusion on Day 1 of Cycles 1 and 4; on Days 8, 15, and 21 of Cycle 1 (cycle duration: 4 weeks)
Reported as:
Mean · micrograms per milliliter
Parts 1 and 2: Serum Concentrations of Tislelizumab
micrograms per milliliterPart 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting)Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)
Cycle 1 Day 1: Pre-infusion0 ± 0—0 ± 00 ± 00 ± 0
Cycle 1 Day 1: End of infusion105 ± 23.5—101 ± 22.774.0 ± NA78.3 ± 19.9
Cycle 1 Day 849.5 ± 12.7—54.4 ± 15.145.2 ± NA39.2 ± 10.0
Cycle 1 Day 1534.3 ± 11.2—31.4 ± 7.6336.7 ± NA27.7 ± 8.72
Cycle 1 Day 2127.3 ± 13.1—28.1 ± 6.58—20.3 ± 5.58
Cycle 2 Day 1: Pre-infusion22.2 ± 8.27—19.3 ± 10.521.5 ± NA15.1 ± 5.14
Cycle 4 Day 1: Pre-infusion29.9 ± 11.8—41.0 ± 15.546.6 ± NA25.1 ± 8.64
Cycle 4 Day 1: End of infusion158 ± 47.6—172 ± 7.78137 ± NA114 ± 25.4
Cycle 7 Day 1: Pre-infusion57.2 ± NA—50.0 ± 31.0—35.5 ± 14.4
Cycle 13 Day 1: Pre-infusion45.9 ± NA—26.0 ± NA—34.9 ± 7.32
SecondaryParts 1 and 2: Number of Patients With Antidrug Antibodies (ADAs) to Tislelizumab

Blood samples were collected at the specified timepoints to detect ADAs to tislelizumab. Treatment-induced ADA was defined as ADA negative at baseline and ADA positive post-baseline. Treatment-boosted ADA was defined as ADA positive at baseline that was boosted to a 4-fold or higher-level following treatment administration.

Time frame:
From the first dose of study treatment (Day 1) up to end of treatment, up to approximately 17 months for Part 1 and 20 months for Part 2
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Patients With Antidrug Antibodies (ADAs) to Tislelizumab
ParticipantsPart 1: Solid Tumor of Any Type (IO-Treated/IO-Naïve in the Metastatic Setting)Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)
Treatment-Induced ADA203010
Treatment-Boosted ADA00002
SecondaryPart 2: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Treatment Discontinuation

An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment, whether or not considered related to the treatment. An AE was considered "serious" if, in the view of either the investigator or sponsor, it resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, was a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, was an abnormal pregnancy outcome in a child born to a female patient/female partner of a male patient exposed to study treatment or was an important medical event. TEAEs were AEs that started or worsened in severity on or after the first dose of study treatment and up to 30 days after the date of last study treatment administration.

Time frame:
From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 21 months
Reported as:
Count of participants · Participants
Part 2: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Treatment Discontinuation
ParticipantsPart 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)
TEAEs111139
TESAEs02120
TEAEs leading to fruquintinib treatment discontinuation1119
TEAEs leading to tislelizumab treatment discontinuation1109
SecondaryPart 2: Change From Baseline in Programmed Death-Ligand 1 (PD-L1) Expression

Expression of PD-L1 biomarker was planned to be assessed in tumor tissues of the patients. Baseline was defined as the last non-missing assessment prior to the first administration of any study treatment (whichever occurred first), including scheduled and unscheduled visits, unless otherwise specified.

Time frame:
Baseline (Day 1) up to end of treatment, up to approximately 20 months

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 18 months for Part 1 and 21 months for Part 2. All-cause mortality (deaths) were collected from Day 1 up to end of follow up, approximately 34 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)1/1 (100%)0/1 (0%)1/1 (100%)
Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)8/11 (72.7%)2/11 (18.2%)11/11 (100%)
Part 2: Cohort C: EC (IO-Naïve)0/1 (0%)1/1 (100%)1/1 (100%)
Part 2: Cohort D: MSS mCRC (IO-Naïve)20/39 (51.3%)20/39 (51.3%)39/39 (100%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventPart 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)
HypertensionVascular disorders0/10/111/10/39
ConstipationGastrointestinal disorders0/11/110/10/39
Disease progressionGeneral disorders0/11/110/12/39
Pain in extremityMusculoskeletal and connective tissue disorders0/11/110/10/39
Abdominal painGastrointestinal disorders0/10/110/13/39
NauseaGastrointestinal disorders0/10/110/12/39
VomitingGastrointestinal disorders0/10/110/12/39
Urinary tract infectionInfections and infestations0/10/110/12/39
HyperbilirubinaemiaHepatobiliary disorders0/10/110/12/39
Depressed level of consciousnessNervous system disorders0/10/110/12/39
Most frequent other events
Showing 10 of 110
Most frequent other events
EventPart 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)
FatigueGeneral disorders0/15/111/126/39
Gait disturbanceGeneral disorders1/10/110/10/39
Platelet count decreasedInvestigations1/11/110/11/39
DehydrationMetabolism and nutrition disorders1/10/110/13/39
HypertensionVascular disorders1/14/111/113/39
ArthralgiaMusculoskeletal and connective tissue disorders1/15/111/15/39
Muscular weaknessMusculoskeletal and connective tissue disorders0/10/111/11/39
Memory impairmentNervous system disorders1/10/111/10/39
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders1/10/110/17/39
Sinus bradycardiaCardiac disorders1/10/110/10/39

Baseline characteristics

The safety analysis set (SAS) included all enrolled patients who received at least 1 dose of fruquintinib or tislelizumab. 1 patient enrolled in Part 1 was also included in Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting) and 5 patients enrolled in Part 1 were also included in Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting).

Age, Categorical
Age, Categorical(Participants)Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)Total
<=18 years00000
Between 18 and 65 years0803240
>=65 years131712
Sex: Female, Male
Sex: Female, Male(Participants)Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)Total
Female11111225
Male0002727
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)Total
Hispanic or Latino01045
Not Hispanic or Latino1913243
Unknown or Not Reported01034
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)Part 2: Cohort B: TNBC (IO-Naïve in the Metastatic Setting)Part 2: Cohort C: EC (IO-Naïve)Part 2: Cohort D: MSS mCRC (IO-Naïve)Total
American Indian or Alaska Native00000
Asian00022
Native Hawaiian or Other Pacific Islander00000
Black or African American01023
White11013143
More than one race00000
Unknown or Not Reported00044
08

Study locations

16 sites
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • Highlands Oncology
    Springdale, Arkansas 72762, United States
  • Beverly Hills Cancer Center
    Beverly Hills, California 90211, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Florida Cancer Specialists - FCS South
    Port Charlotte, Florida 33980, United States
  • Florida Cancer Center North
    St. Petersburg, Florida 33709, United States
  • Florida Cancer Specialists Panhandle
    Tallahassee, Florida 32308, United States
  • Florida Cancer Specialists - East (FCS East)
    West Palm Beach, Florida 33401, United States
  • HOC AON Baton Rouge / Sarah Cannon
    Baton Rouge, Louisiana 70809, United States
  • Messino Cancer Center
    Asheville, North Carolina 28806, United States
  • Oklahoma University Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Women and Infants Hospital of Rhode Island
    Providence, Rhode Island 02905, United States
  • Tennessee Oncology-Chattanooga
    Chattanooga, Tennessee 37404, United States
  • Tennesse Oncology
    Nashville, Tennessee 37203, United States
  • Vanderbilt Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Jun 2024, 34 months.

Results were first posted in Jul 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2020
First posted
Oct 8, 2020
StartActual
Aug 9, 2021
Primary completionActual
Jun 18, 2024
CompletionActual
Jun 18, 2024
Results first posted
Jul 14, 2025
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04577963
Lead sponsor
Hutchmed
Collaborators
BeiGene
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Aug 9, 2021
Primary completion
Jun 18, 2024
Completion
Jun 18, 2024
Results posted
Jul 14, 2025
Last update
Jul 14, 2025

Study contacts

William Schelman, MD, PhD
study director · HUTCHMED International

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HMPL-013 · Tislelizumab

Start the discussion